{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:41:35Z","timestamp":1747183295501,"version":"3.40.5"},"reference-count":50,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Paediatrica"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To describe a rare case of primary refractory Hodgkin lymphoma nodular sclerosis syncytial variant in a child and review immunotherapy in relapsed\/refractory Hodgkin lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We described the treatment course of a child with primary refractory classic Hodgkin lymphoma and discussed different options for salvage therapy, with an emphasis on immunotherapy. We searched PubMed for all published clinical trials investigating immunotherapy in classic Hodgkin lymphoma written in English until 31 June, 2023. The reference list of each identified paper was searched for additional publications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our patient was salvaged with anti\u2010programmed cell death 1 (PD\u20101) antibody therapy followed by high\u2010dose chemotherapy with autologous stem cell rescue. Radiotherapy was avoided. We identified five one\u2010armed phase II trials investigating anti\u2010PD\u20101 therapy in first relapse\/refractory disease in a total of 254 patients aged 9\u201371\u2009years, of which one included 31 children. The complete remission rate before high\u2010dose chemotherapy was 59%\u201395% overall and 67%\u201389% among those with refractory disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although it remains to be proven in randomised trials, anti\u2010PD\u20101 therapy may provide higher complete response rates than traditional chemotherapy. Anti\u2010PD\u20101 therapy has the potential to increase the chance of cure while decreasing the risk of late effects from chemotherapy and radiotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apa.17235","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T07:59:20Z","timestamp":1712735960000},"page":"1483-1495","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy \u2013 A case report and literature review"],"prefix":"10.1111","volume":"113","author":[{"given":"Nina","family":"Mogensen","sequence":"first","affiliation":[{"name":"Paediatric Oncology Unit, Astrid Lindgren Children's Hospital Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Cananau","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-0371","authenticated-orcid":false,"given":"Susanna","family":"Ranta","sequence":"additional","affiliation":[{"name":"Paediatric Oncology Unit, Astrid Lindgren Children's Hospital Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Karl\u00e9n","sequence":"additional","affiliation":[{"name":"Paediatric Oncology Unit, Astrid Lindgren Children's Hospital Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kwiecinska","sequence":"additional","affiliation":[{"name":"Department of Pathology Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1333-2912","authenticated-orcid":false,"given":"Fredrik","family":"Baecklund","sequence":"additional","affiliation":[{"name":"Paediatric Oncology Unit, Astrid Lindgren Children's Hospital Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2017.1355563"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0021"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy080"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18083"},{"volume-title":"Swedish National Guidelines on Hodgkin lymphoma","year":"2022","author":"Hodgkins lymfom \u2010 Nationellt v\u00e5rdprogram version 4.0","key":"e_1_2_11_6_1"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0027"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00470-8"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00019-0"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000329"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.3.616"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf221"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg496"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm090"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10661"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4466"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.018"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-815183"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz009"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00170-8"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243238"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01056"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015423"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7975"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017118"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09199.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388058"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31114"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2021.05.008"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018827"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01204-6"},{"key":"e_1_2_11_35_1","unstructured":"Opdivo.European Medicines Agency. 11 June 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries\u2010opinion\/opdivo\u20109."},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0004"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_11_39_1","unstructured":"Keytruda.European Medicines Agency. 11 June 2023.https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp\u2010post\u2010authorisation\u2010summary\u2010opinion\u2010keytruda\u2010ii\u2010111_en.pdf."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30671-0"},{"key":"e_1_2_11_43_1","doi-asserted-by":"crossref","unstructured":"HerreraAF LeBlancM CastellinoSM et\u00a0al.SWOG S1826 a randomized study of nivolumab(N)\u2010AVD versus brentuximab vedotin(BV)\u2010AVD in advanced stage (AS) Classic Hodgkin Lymphoma (HL). 2023 ASCO Annual Meeting. Chicago Illinois USA: American Society of Clinical Oncology2023.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0750"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00318-0"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2021.11.007"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.01.011"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01721-w"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3262"}],"container-title":["Acta Paediatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apa.17235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T04:12:23Z","timestamp":1718079143000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apa.17235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/apa.17235"],"URL":"https:\/\/doi.org\/10.1111\/apa.17235","archive":["Portico"],"relation":{},"ISSN":["0803-5253","1651-2227"],"issn-type":[{"type":"print","value":"0803-5253"},{"type":"electronic","value":"1651-2227"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"2024-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}